CD25
CD25
IL-15
Natural killer cells
regulatory T cells
tumor microenvironment
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
28
3
2023
entrez:
27
3
2023
pubmed:
28
3
2023
Statut:
epublish
Résumé
Infusion of natural killer (NK) cells is an attractive therapeutic modality in patients with cancer. However, the activity of NK cells is regulated by several mechanisms operating within solid tumors. Regulatory T (Treg) cells suppress NK cell activity through various mechanisms including deprivation of IL-2 via the IL-2 receptor alpha (CD25). Here, we investigate CD25 expression on NK cells to confer persistence in Treg cells containing solid tumor models of renal cell carcinoma (RCC). Compared with IL-2, stimulation with IL-15 increases the expression of CD25 resulting in enhanced response to IL-2 as evidenced by increased phosphorylation of STAT5. Compared with CD25
Identifiants
pubmed: 36970070
doi: 10.1080/2162402X.2023.2175517
pii: 2175517
pmc: PMC10038043
doi:
Substances chimiques
Interleukin-15
0
Interleukin-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2175517Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
The authors have no relevant competing interests to declare.
Références
Front Immunol. 2021 Dec 17;12:730970
pubmed: 34975835
J Exp Med. 2005 Oct 17;202(8):1075-85
pubmed: 16230475
Retrovirology. 2015 Jul 30;12:66
pubmed: 26220086
Nat Immunol. 2014 Aug;15(8):749-757
pubmed: 24973821
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Oncoimmunology. 2013 Mar 1;2(3):e23562
pubmed: 23687622
JCI Insight. 2018 Feb 8;3(3):
pubmed: 29415897
Cell Mol Immunol. 2015 Jan;12(1):77-86
pubmed: 24793405
JCI Insight. 2017 Dec 7;2(23):
pubmed: 29212951
J Immunother. 2013 Nov-Dec;36(9):462-7
pubmed: 24145357
Cytotherapy. 2012 Jan;14(1):91-103
pubmed: 21973023
EMBO Rep. 2021 Mar 3;22(3):e51329
pubmed: 33480074
J Transl Med. 2015 Apr 14;13:120
pubmed: 25889680
Blood. 2016 Sep 15;128(11):1475-89
pubmed: 27465917
Immunity. 2007 Oct;27(4):635-46
pubmed: 17919943
Cytotherapy. 2021 Jul;23(7):559-566
pubmed: 33431318
PLoS One. 2017 Aug 9;12(8):e0182532
pubmed: 28792982
J Immunol. 2007 Sep 15;179(6):3578-87
pubmed: 17785792
J Clin Invest. 2020 Oct 1;130(10):5508-5522
pubmed: 32673292
Cancer Discov. 2021 Jan;11(1):34-44
pubmed: 33277307
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nat Immunol. 2007 Dec;8(12):1353-62
pubmed: 17982458
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Biol Blood Marrow Transplant. 2014 Apr;20(4):463-73
pubmed: 24434782
J Exp Med. 2013 Jun 3;210(6):1153-65
pubmed: 23650440
Cancers (Basel). 2020 Jul 02;12(7):
pubmed: 32630675
Cancer Cell Int. 2021 Mar 4;21(1):152
pubmed: 33663530